(Reaffirmed October 2024)| www.acog.org
The anti-abortion plaintiffs in this case are challenging the 2016 and 2021 rules issued by the FDA, both of which greatly increased mifepristone access. The 2016 change updated the mifepristone label to allow the drug to be used for up to 10 weeks of pregnancy, instead of the earlier seven. Prior to 2016, just 37% of all US abortions were eligible for mifepristone. After the 2016 change, that number jumped to 75%. The 2021 rule removed a requirement that mifepristone be dispensed through 3 i...| Positive Women's Network - USA